)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Castle Biosciences
Castle Biosciences (CSTL) investor relations material
Castle Biosciences Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 revenue rose 23.9% YoY to $102.9M, led by TissueCypher report volume growth of 47%; nine-month revenue increased 12.8% to $290.1M.
FY2026 revenue guidance increased to $385M–$395M from $365M–$375M; Q3 Adjusted EBITDA was $12.7M.
Financial highlights
Q3 GAAP revenue was $102.891M; Adjusted Revenue was $101.947M after a $944K net adjustment for reports delivered in prior periods.
Q3 net loss was $4.1M versus $0.5M YoY; nine-month net loss narrowed to $20.7M from $21.8M.
Q3 operating loss improved to $2.7M from $6.8M; nine-month operating loss improved to $24.2M from $39.0M.
Q3 Adjusted EBITDA was $12.719M versus $9.2M YoY; nine-month Adjusted EBITDA was $20.0M versus $32.5M.
Q3 operating expenses, including cost of sales, were $105.6M versus $89.8M YoY; higher costs reflected staffing, growth support and operating needs.
Outlook and guidance
FY2026 revenue guidance rose to $385M–$395M from $365M–$375M, a $20M increase at the midpoint and a $45M increase from initial February guidance.
The guidance increase primarily reflects expected TissueCypher volume growth and, to a lesser extent, ASP improvement; TissueCypher volume growth guidance remains 50%–52%.
Positive Adjusted EBITDA is expected in Q4 and full-year 2026, and in FY2027 assuming no change in strategic direction.
DecisionDx-Melanoma volume growth is expected in the mid-single digits for FY2026; Q4 may be seasonally lighter due to holiday disruptions in medical practices.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Castle Biosciences
- Revenue more than doubled, the IPO bolstered cash, and pipeline launches targeted 2H20.CSTL
Q4 2019 - Revenue rose 20.8%, but investment and pandemic pressures drove a $10.3M loss.CSTLQ4 2020
- Revenue grew 50.2% as portfolio expansion accelerated, while net losses widened.CSTLQ4 2021
- Revenue grew 46%, while losses widened as commercial and R&D investment accelerated.CSTLQ4 2022
- TissueCypher volumes surged 63% YoY, with AI and new launches set to drive future growth.CSTL2026 Global Healthcare Conference
- Growth in core tests and new launches, with positive EBITDA outlook through 2027.CSTLCanaccord Genuity's 46th Annual Growth Conference
- Q2 2026 saw 32% core test volume growth, $103.5M revenue, and raised annual guidance.CSTLCorporate presentation
- Q2 2026 revenue up 20% to $103.5M; core test volumes rose 32% and guidance was raised.CSTLQ2 2026
- Q3 2024 revenue up 39% to $85.8M, guidance raised on strong test adoption and profitability.CSTLQ3 2024
Next Castle Biosciences earnings date
Stephens Annual Investment Conference18 Nov, 2026
Castle Biosciences
Next Castle Biosciences earnings date
Stephens Annual Investment Conference18 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Castle Biosciences is a provider of products that assesses the response of cancer patients to treatment. The company's products include Immunoscore non-invasive test, which measures changes in proteins expressed on the surface of a person's tumor; CastleTRAC, a diagnostic tool for assessing the tissue response in four types of cutaneous T-cell lymphomas (CTCL); and CastleMAP for measuring the immune reaction to a specific drug. Castle Biosciences, Inc., is based in Friendswood, Texas.